CBAY

Cymabay Therapeutics
CBAY

Overview Fund Activity
Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

118 hedge funds and large institutions have $213M invested in Cymabay Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
118
Holders Change
+5
Holders Change %
+4.42%
% of All Funds
1.87%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
22
Increased
38
Reduced
25
Closed
17
Calls
$805K
Puts
$456K
Net Calls
+$349K
Net Calls Change
+$956K

Top Buyers

1
CC
Commodore Capital
New York
$17.8M
2
Millennium Management
Millennium Management
New York
$7.38M
3
Citadel Advisors
Citadel Advisors
Florida
$3.01M
4
Renaissance Technologies
Renaissance Technologies
New York
$1.43M
5
HS
HighVista Strategies
Massachusetts
$645K

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
$0
2
SCM
Stonepine Capital Management
Oregon
$0
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
$0
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
$31.1K
5
NCM
Nantahala Capital Management
Connecticut
$5.89M
Name Holding Trade Value Shares
Change 		Shares
Change %
TC
126
Truvestments Capital
Florida
– -$2K -727 Closed
AWA
127
Amplius Wealth Advisors
Pennsylvania
– -$1K -550 Closed
MPWT
128
MassMutual Private Wealth & Trust
Connecticut
– -$1K -178 Closed
2 3 4 5
6